Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1
119 posts, 0 comments

8/9/23 – RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

August 9, 2023j3ff1
Read More

5/24/23 – ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

May 24, 2023j3ff1
Read More

4/5/23 – RespireRx Pharmaceuticals Inc. Establishes Research Collaboration with University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

April 5, 2023j3ff1
Read More

4/3/23 – RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation

April 3, 2023j3ff1
Read More

3/28/23 – RespireRx Pharmaceuticals Inc. Announces the Appointment of Joseph Siegelbaum as an Independent Member of the Board of Directors

March 28, 2023j3ff1
Read More

3/1/23 – ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd

March 1, 2023j3ff1
Read More

2/1/23 – ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

February 1, 2023j3ff1
Read More

1/23/23 – RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois

January 23, 2023j3ff1
Read More

1/12/23 – RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform

January 23, 2023j3ff1
Read More

12/5/22 – RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development

December 5, 2022j3ff1
Read More

Posts navigation

1 2 3 4 … 12 >

RespireRx Organization Structure

  • RespireRx Organization Structure
  • Arnold S. Lippa, PhD
    • Richard Purcell
    • David Dickason
    • James Cook
    • Jeffrey M. Witkin
    • Rok Cerne
  • Jeff Margolis
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.